1445379-59-8

Basic information

• Product Name: 3'-O-(t-Butyldimethylsilyl)-2'-deoxy-2'-fluorouridine
• Synonyms: 3'-O-(t-Butyldimethylsilyl)-2'-deoxy-2'-fluorouridine;2'-Deoxy-3'-O-[(1,1-dimethylethyl)dimethylsilyl]-2'-fluorouridine
• CAS NO: 1445379-59-8
• Molecular Formula: C15H25FN2O5Si
• Molecular Weight: 360.45
• Mol File: 1445379-59-8.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly, Sonicated), DMSO (Slightly), Methanol (Slightly, Sonicated
• CAS DataBase Reference: 3'-O-(t-Butyldimethylsilyl)-2'-deoxy-2'-fluorouridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3'-O-(t-Butyldimethylsilyl)-2'-deoxy-2'-fluorouridine(1445379-59-8)
• EPA Substance Registry System: 3'-O-(t-Butyldimethylsilyl)-2'-deoxy-2'-fluorouridine(1445379-59-8)

Safety Data

• Hazardous Substances Data: 1445379-59-8(Hazardous Substances Data)

Usage

Description

3'-O-(t-Butyldimethylsilyl)-2'-deoxy-2'-fluorouridine is a chemical compound that serves as an intermediate in the synthesis of various nucleotide and nucleoside therapeutics. It is characterized by the presence of a t-butyldimethylsilyl group at the 3' position and a fluorine atom at the 2' position, which contributes to its unique properties and potential applications in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
3'-O-(t-Butyldimethylsilyl)-2'-deoxy-2'-fluorouridine is used as a synthetic intermediate for the preparation of 4'-halogen containing nucleotide and nucleoside therapeutics. Its unique structure allows for the development of novel therapeutic agents with potential applications in the treatment of various diseases, including cancer and viral infections.
In the synthesis of nucleotide and nucleoside therapeutics, 3'-O-(t-Butyldimethylsilyl)-2'-deoxy-2'-fluorouridine serves as a key building block. The presence of the t-butyldimethylsilyl group provides stability and reactivity control during the synthesis process, while the fluorine atom at the 2' position introduces unique properties that can be exploited for the development of new drugs with improved efficacy and selectivity.
Overall, 3'-O-(t-Butyldimethylsilyl)-2'-deoxy-2'-fluorouridine is a valuable compound in the pharmaceutical industry, playing a crucial role in the development of innovative nucleotide and nucleoside-based therapeutics with potential applications in the treatment of a wide range of diseases.

Upstream product

• 56287-17-3 2'-deoxy-2'-fluorouridine 
• 69123-94-0 1-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)uracil 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 1445379-61-2 4'-α-methylhydroxyl-3'-tert-butyldimethylsilyl-2'-deoxy-2'-fluorouridine 
• 1445379-64-5 3'-O-(tert-butyldimethylsilyl)-5′-O-(tert-butyldiphenylsilyl)-2′-deoxy-2′-fluoro-4′-hydroxymethyluridine 
• 1445379-66-7 C₃₂H₄₃FN₂O₆Si₂ 
• 1445379-68-9 C₃₃H₄₅FN₂O₅Si₂ 
• 1445379-70-3 C₃₃H₄₆FN₃O₄Si₂ 
• 1445379-72-5 C₃₃H₄₈FN₃O₄Si₂ 
• 1445379-78-1 C₃₃H₄₇FN₂O₅Si₂ 
• 1445379-88-3 C₃₂H₄₄ClFN₂O₅Si₂ 
• 1445379-90-7 C₃₂H₄₅ClFN₃O₄Si₂ 
• 1445379-96-3 C₃₂H₄₄FIN₂O₅Si₂ 
• 1445379-98-5 C₃₂H₄₅FN₂O₅Si₂ 
• 1445380-00-6 C₃₂H₄₆FN₃O₄Si₂ 
• 1445380-06-2 C₃₄H₄₅FN₂O₆Si₂ 
• 1445380-08-4 C₃₄H₄₅FN₂O₅Si₂ 

Relevant articles and documents

Exploring Atypical Fluorine–Hydrogen Bonds and Their Effects on Nucleoside Conformations

The ability of fluorine to serve as a hydrogen-bond acceptor has been debated for many years. Short fluorine–hydrogen contacts are thought to play a key role in stabilizing some complex supramolecular systems. To directly probe the existence of fluorine–hydrogen bonds, we have performed NMR spectroscopy and computational modeling on a series of C2′-fluorinated nucleosides. Specifically, quantum mechanics/molecular mechanics (QM/MM) analysis and [19F,1H] HMBC NMR experiments provided direct evidence for a C?H???F hydrogen bond in a 2′-F,4′-C-α-alkyl-ribonucleoside analogue. This interaction was also supported by QTAIM and NBO analyses, which confirmed a bond critical point for the C?H???F interaction (0.74 kcal mol?1). In contrast, although conformational analysis and NMR experiments of 2′-deoxy-2′-fluoro-arabinonucleosides indicated a close proximity between the 2′-fluorine and the H6/8 protons of the nucleobase, molecular simulations did not provide evidence for a C?H???F hydrogen bond.

S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS

Various embodiments provide STOPS? polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS? modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS? modified oligonucleotides, as determined by HBsAg Secretion Assay, is an EC50 that is less than 100 nM.

CHIRALLY-ENRICHED DOUBLE-STRANDED RNA AGENTS

The present invention relates to a chirally-modified dsRNA agent capable of inhibiting the expression of a target gene. The sense and antisense strands of chirally-modified dsRNA agent independently or in combination comprises one or more site specificsit